CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated

Size: px
Start display at page:

Download "CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated"

Transcription

1 INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record stage of disease - contrast enhanced CT scan (neck, chest, abdomen and pelvis) and/or PET scan, presence or absence of B symptoms, clinical extent of disease, cardiac function, bone marrow trephine. 3. Blood tests - FBC, U&Es, LDH, ESR, urate, calcium, magnesium, creatinine, LFTs, glucose, Igs, hepatitis B core antibody and hepatitis BsAg, hepatitis C antibody, EBV, CMV, VZV, HIV 1+2 after consent, group and save. 4. Cerebrospinal fluid examination if clinically indicated or lymphomatous involvement in bone marrow, orbit, nasal/paranasal sinuses, orbit, testis, peripheral blood and bone. 5. Urine pregnancy test - before cycle 1 of each new chemotherapy course for women of childbearing age unless they are post-menopausal, have been sterilised or undergone a hysterectomy. 6. ECG and Echo. 7. Record performance status (WHO/ECOG). 8. Record vital signs, height and weight. 9. Consent - ensure patient has received adequate verbal and written information regarding their disease, treatment and potential side effects. Document in medical notes all information that has been given. Obtain written consent on the day of treatment. 10. Fertility - it is very important the patient understands the potential risk of infertility, all patients should be offered fertility advice by referring to the Oxford Fertility Unit. 11. Hydration - in patients with bulky disease pre-hydrate with sodium chloride 0.9% rate as per clinician discretion Patients at high risk of tumour lysis refer to tumour lysis protocol. 12. Consider dental assessment / Advise dental check is carried out by patient's own dental practitioner before treatment starts. 13. Treatment should be agreed in the relevant MDT. This is a controlled document and therefore must not be changed or photocopied 1 of 5

2 DRUG REGIMEN Day 1 Pre med - Paracetamol 1g PO, Chlorphenamine 10 mg IV, and Day 1 Prednisolone 30 minutes before rituximab. RITUXIMAB 375 mg/m 2 IV infusion daily in 500 ml sodium chloride 0.9%. VINCRISTINE 1.4 mg/m 2 (maximum 2 mg*) IV infusion in 50 ml sodium chloride 0.9% over 10 minutes. CYCLOPHOSPHAMIDE 750 mg/m 2 IV bolus GEMCITABINE** 750 mg/m 2 IV infusion in 250 ml sodium chloride 0.9% Days 1 to 5 PREDNISOLONE 100mg PO daily. (Give first dose before rituximab as pre-med). Day 8 GEMCITABINE** 750 mg/m 2 IV infusion in 250 ml sodium chloride 0.9% * Max. Vincristine dose 2 mg (consider capping at 1 mg in over 70 year old patients). ** The Gemcitabine dose is escalated to 875 mg/m 2 for cycle 2 and then 1 g/m 2 for successive cycles if no toxicity is observed. Primary G-CSF prophylaxis should be used according to local policy (e.g. filgrastim for 7 days starting on day 9). CYCLE FREQUENCY Cycle repeats every 21 days for 6 cycles. RESTAGING Re-stage with Interim CT scan after 4 courses of treatment to ensure response. PET/CT or contrast enhanced CTat completion of treatment. Consider repeat Bone Marrow Biopsy at end of treatment if initially involved and clinically appropriate This is a controlled document and therefore must not be changed or photocopied 2 of 5

3 DOSE MODIFICATIONS Toxicity 1. Haematological Toxicity ANC (x10 9 /L) Platelets (x10 9 /L) Gemcitabine % 100% < <75 75% 75% <0.5 <50 Day 1: Delay until ANC 1 and platelets 75, then 100% dose. Day 8: Omit dose Cyclophosphamide & Vincristine Delay until ANC 1 and platelets 75, then 100% dose. *Dose modifications due to haematological toxicities should only be made according to the blood count on the day of treatment. Febrile neutropenia Haemorrhage with thrombocytopenia 2. Non-haematological Toxicity Grade 3 (expect nausea & vomiting, alopecia) Grade 4 Delay until recovery. If recurrent, then 75% dose in subsequent courses. Delay until recovery, then 75% dose in subsequent courses. Delay until recovery. If recurrent, then 75% dose in subsequent courses. Delay until recovery, then 75% dose in subsequent courses. 75% in subsequent courses. 75% in subsequent courses. Delay until recovery, then 50% in subsequent courses. Delay until recovery, then 50% in subsequent courses. Gemcitabine: CrCl <30 ml/min consider dose reduction - Clinical decision Gemcitabine: limited information, consider dose reduction if bilirubin elevated - e.g. if bilirubin >27 micromol/l, consider initiating at 80% dose. Vincristine: Bilirubin micromol/l or ALT/AST u/l 50% dose Bilirubin >51 micromol/l & normal ALT/AST 50% dose Bilirubin >51 micromol/l & ALT/ AST >180 u/l omit Vincristine In the presence of motor weakness or severe sensory symptoms, discuss reducing or withholding vincristine with a consultant. This is a controlled document and therefore must not be changed or photocopied 3 of 5

4 Cyclophosphamide: GFR (ml/min) Dose >20 100% % <10 50% Clinical decision consider whether patient is being treated with high dose treatment. Clinical decision. Exposure to active metabolites may not be increased, suggesting dose reduction may not be necessary. INVESTIGATIONS FBC, renal and liver profiles, only FBC result essential prior to administration of chemotherapy. CONCURRENT MEDICATION Allopurinol Co-trimoxazole Ranitidine or PPI Aciclovir G-CSF 300 mg daily for 7 days starting hours prior to chemotherapy (first course / cycle only) 480 mg OD PO (Mon, Wed and Fri) to treatment end plus 3 months Daily for the duration of steroid treatment in regimen 200 mg TDS until 3 months after last course from Day 9 as per local policy. EMETIC RISK Moderate. ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS Cyclophosphamide may irritate the bladder mucosa. Patients should be encouraged to drink a minimum of three litres of fluid per 24 hrs. Vincristine may cause neurotoxicity. Gemcitabine may cause elevation of liver transaminases (AST and ALT), increased bilirubin and alkaline phosphatise, haematuria, oedema/peripheral oedema. Rituximab may cause patient chillness, fever, headache, tiredness, aching muscles and joints, itching redness of skin, nausea and mild drop in blood pressure. Hepatitis B reactivation. Steroid side effects monitor BMs. This is a controlled document and therefore must not be changed or photocopied 4 of 5

5 TREATMENT RELATED MORTALITY 2-5% REFERENCES 1. Fields P, Webb A, Pocock CFE, Townsend W, Smith P, Kirkwood A, El-Mehiki N, Johnson PW, Radford J, Linch DC, Cunningham D. First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone () for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: UCLH - Dosage Adjustment for Cytotoxics in Hepatic Impairment ( 3 - updated January 2009). 3. UCLH - Dosage Adjustment for Cytotoxics in Renal Impairment ( 3 - updated January 2009). This is a controlled document and therefore must not be changed or photocopied 5 of 5

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21 R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed

More information

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology

More information

DA-EPOCH-R (Etoposide/Inpatient)

DA-EPOCH-R (Etoposide/Inpatient) DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record

More information

O-CVP with maintenance Obinutuzumab

O-CVP with maintenance Obinutuzumab with maintenance Obinutuzumab INDICATION Follicular Lymphoma: 1 st line treatment in advanced symptomatic patients (NICE TA513 for FLIPI score 2 or higher - BLUETEQ required) TREATMENT INTENT Disease modification.

More information

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin : Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin

More information

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin : Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.

More information

NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details.

NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details. DA- INDICATION High grade lymphoma. Omit rituximab if CD20 negative. NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details. TREATMENT INTENT Curative

More information

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient.

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient. INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within

More information

Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma.

Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma. INDICATION Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy

More information

BEACOPP-14/ BEACOPP- Escalated

BEACOPP-14/ BEACOPP- Escalated BEACOPP-14/ BEACOPP- Escalated INDICATION Early Stage Classical Hodgkin Lymphoma with positive interim PET-CT (Deauville 3 or more) Advanced Classical Hodgkin lymphoma This protocol should normally be

More information

(primary CNS lymphoma)

(primary CNS lymphoma) (primary CNS lymphoma) INDICATION CNS Lymphoma TREATMENT INTENT Curative PRE-ASSESSMENT 1. Ensure histology is confirmed and documented in the notes. Although it is sometimes difficult to obtain tissue

More information

ALL Phase 2 Induction (25-60 years)

ALL Phase 2 Induction (25-60 years) ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients

More information

2.07 Protocol Name: CHOP & Rituximab

2.07 Protocol Name: CHOP & Rituximab 2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing

More information

ALL MAINTENANCE (25-60 years)

ALL MAINTENANCE (25-60 years) ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may

More information

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details

More information

SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone)

SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone) SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone) INDICATION Natural Killer/T-cell lymphoma TREATMENT INTENT Curative SPECIAL PRECAUTIONS This protocol causes marked myelosuppression despite

More information

(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.

(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab. (R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell

More information

X M/ (R) Dose adjusted (DA)-EPOCH-R

X M/ (R) Dose adjusted (DA)-EPOCH-R X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell

More information

ALL Phase 1 Induction (25-60 years)

ALL Phase 1 Induction (25-60 years) ALL Phase 1 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients

More information

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer

More information

ALL CONSOLIDATION- Cycle 3 (25-60 years)

ALL CONSOLIDATION- Cycle 3 (25-60 years) ALL CONSOLIDATION- (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It

More information

(High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA)

(High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA) MATRix (High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA) INDICATION CNS Lymphoma. TREATMENT INTENT Curative. PRE-ASSESSMENT 1. Ensure histology is confirmed and documented in the notes.

More information

Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:

Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen R-GCVP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication CD 20 positive

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME CEOP.DOC CONTROLLED DOC NO: HCCPG B21 CSIS Regimen Name: CEOP. CEOP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME CEOP.DOC CONTROLLED DOC NO: HCCPG B21 CSIS Regimen Name: CEOP. CEOP Regimen CEOP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication T-cell non-hodgkin

More information

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes. R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

More information

Rituximab-CHOP Regimen - ENRICH Study

Rituximab-CHOP Regimen - ENRICH Study Rituximab-CHOP Regimen - Study Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma ***See protocol for further details***

More information

This is a controlled document and therefore must not be changed

This is a controlled document and therefore must not be changed AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System

More information

Carboplatin / Gemcitabine Gynaecological Cancer

Carboplatin / Gemcitabine Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously

More information

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for

More information

BEAM. Lymphoma group OxBMT SCHEDULE SUMMARY. Date:

BEAM. Lymphoma group OxBMT SCHEDULE SUMMARY. Date: xbt SCHEDULE SUARY Date: Day DRUG -7-6 -5-4 -3-2 -1 0 +1 Admission Carmustine (BCNU) Etoposide Cytarabine (Ara-C) elphalan Stem cell infusion Pentamidine* To prevent a specific pneumonia called PCP Cyclizine

More information

NECN CHEMOTHERAPY HANDBOOK PROTOCOL

NECN CHEMOTHERAPY HANDBOOK PROTOCOL DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1* to 5 Prednisolone 40mg/m 2 Oral Once Daily For 5 days 1 Paracetamol 1gram Oral Once Only Chlorphenamine 10mg IV bolus Ondansetron 8mg IV

More information

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A

More information

Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC)

Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC) Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC) Available for Routine Use in Burton in-patient Derby in-patient (First cycle if bulky disease & risk of tumour lysis syndrome) Burton day-case Derby

More information

NCCP Chemotherapy Protocol. CHOEP Therapy 21 days. Treatment of T-cell Non-Hodgkins Lymphoma C a

NCCP Chemotherapy Protocol. CHOEP Therapy 21 days. Treatment of T-cell Non-Hodgkins Lymphoma C a CHOEP Therapy 21 days INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of T-cell Non-Hodgkins Lymphoma C85 00396a ELIGIBILTY: Indication as above Age < 60 years Adequate haematological, renal

More information

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory

More information

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case

More information

LD-ARA-C and Clofarabine

LD-ARA-C and Clofarabine LD-ARA-C and Clofarabine INDICATION Induction plus consolidation chemotherapy for patients with acute myeloid leukaemia (AML). Its use is particularly for patients over 60 years of age but it can be applied

More information

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen

More information

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

Gemcitabine, Dexamethasone and Cisplatin GDP Regimen

Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach

More information

Gemcitabine + Cisplatin Regimen

Gemcitabine + Cisplatin Regimen Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication

More information

PVACE-BOP (Hodgkin s Lymphoma)

PVACE-BOP (Hodgkin s Lymphoma) DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion

More information

Doxorubicin and Ifosfamide Sarcoma

Doxorubicin and Ifosfamide Sarcoma Systemic Anti Cancer Treatment Protocol Doxorubicin and Ifosfamide Sarcoma PROTOCOL REF: MPHADOXIFO (Version No:.0) Approved for use in: Soft tissue sarcoma Dosage: Drug Dosage Route Frequency Doxorubicin

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt

More information

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab

More information

Breast Pathway Group EC x 4: Epirubicin & Cyclophosphamide in Early Breast Cancer

Breast Pathway Group EC x 4: Epirubicin & Cyclophosphamide in Early Breast Cancer Breast Pathway Group EC x 4: & in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for moderate to high risk breast cancer Regimen details: 90 mg/m 2 IV Day 1 600 mg/m 2 IV Day 1 Administration:

More information

TIP Paclitaxel, Ifosfamide and Cisplatin

TIP Paclitaxel, Ifosfamide and Cisplatin Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage

More information

Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma

Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma Systemic Anti Cancer Treatment Protocol Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma PROTOCOL REF: MPHAVIDE (Version No: 1.0) Approved for use in: Ewings sarcoma Desmoplastic small round

More information

(R) CODOX M / (R) IVAC

(R) CODOX M / (R) IVAC (R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor

More information

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available

More information

in people with intermediate 2 or high-risk disease, AND if the company provides ruxolitinib with the discount agreed in the patient access scheme.

in people with intermediate 2 or high-risk disease, AND if the company provides ruxolitinib with the discount agreed in the patient access scheme. RUXOLITINIB INDICATION Licensed / NICE TA386 is recommended as an option f treating disease-related splenomegaly symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis),

More information

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton

More information

Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in

More information

Cisplatin and Gemcitabine Bladder Cancer: Full and split dose

Cisplatin and Gemcitabine Bladder Cancer: Full and split dose Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications

More information

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in

More information

4.05 Protocol name: Alemtuzumab (MabCampath ), intravenous

4.05 Protocol name: Alemtuzumab (MabCampath ), intravenous 4.05 Protocol name: (MabCampath ), intravenous Indication Treatment of CLL refractory to fludarabine (either primary i.e. 17p deletion, or secondary i.e. following previous fludarabine treatment), without

More information

TREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.

TREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals. BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)

More information

O-CHOP with Obinutuzumab maintenance

O-CHOP with Obinutuzumab maintenance O-CHOP with Obinutuzumab maintenance Indication Adult patients with untreated advanced follicular lymphoma with Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or above. (NICE TA513)

More information

Breast Pathway Group Docetaxel in Advanced Breast Cancer

Breast Pathway Group Docetaxel in Advanced Breast Cancer Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not

More information

Gemcitabine + Capecitabine (ESPAC-4 Trial)

Gemcitabine + Capecitabine (ESPAC-4 Trial) Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***

More information

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO: OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community

More information

Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant therapy in early breast cancer Regimen details: Fluorouracil 600mg/m

More information

DTPACE. Myeloma group INDICATION

DTPACE. Myeloma group INDICATION INDICATION Relapsed or refractory myeloma patients suitable for intensive salvage chemotherapy. Plasma cell leukaemia or presentation with extra-medullary disease. TREATMENT INTENT Disease Modification

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen ESHAP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory

More information

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma

More information

Carboplatin and Gemcitabine

Carboplatin and Gemcitabine Systemic Anti Cancer Treatment Protocol Carboplatin and Gemcitabine PROTOCOL REF: MPHACAGELU (Version No: 1.0) Approved for use in: Advanced non-small cell lung cancer Performance status: 0 to 2 Re-challenge

More information

NCCP Chemotherapy Regimen

NCCP Chemotherapy Regimen Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide

More information

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

E 90 C followed by Weekly Paclitaxel

E 90 C followed by Weekly Paclitaxel E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient

More information

Carboplatin + Paclitaxel Cancer of the Cervix

Carboplatin + Paclitaxel Cancer of the Cervix Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they

More information

NCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T)

NCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T) Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T) Note: There is an option for DOXOrubicin, cyclophosphamide followed by weekly PACLItaxel

More information

NCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)

NCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) INDICATIONS FOR USE: INDICATION Adjuvant Treatment of High Risk Node Negative or Node Positive

More information

Paclitaxel Gynaecological Cancer

Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly

More information

Cisplatin and Gemcitabine (bladder)

Cisplatin and Gemcitabine (bladder) Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional

More information

Cisplatin Doxorubicin Sarcoma

Cisplatin Doxorubicin Sarcoma Systemic Anti Cancer Treatment Protocol Cisplatin Doxorubicin Sarcoma PROCEDURE REF: MPHACISDOX (Version No. _1.0) Approved for use in: Osteosarcoma Palliative / advanced disease Not suitable for PAM schedule

More information

CARFILZOMIB /DEXAMETHASONE (CarDex)

CARFILZOMIB /DEXAMETHASONE (CarDex) CARFILZOMIB /DEXAMETHASONE (CarDex) INDICATIONS First Relapse multiple myeloma in bortezomib naïve patients [NICE TA457] Requires Blueteq Application TREATMENT INTENT Disease modification PRE-ASSESSMENT

More information

Gemcitabine & Cisplatin

Gemcitabine & Cisplatin Gemcitabine & Cisplatin Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Advanced

More information

CISPLATIN Chemo-radiation regimen Gynaecological Cancer

CISPLATIN Chemo-radiation regimen Gynaecological Cancer Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)

More information

Carfilzomib and Dexamethasone (CarDex)

Carfilzomib and Dexamethasone (CarDex) Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes

More information

Weekly Cisplatin + Radiotherapy - Interlace study -

Weekly Cisplatin + Radiotherapy - Interlace study - Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with

More information

The drug cost of lenalidomide for people who remain on treatment for more than 26 cycles will be met by the company.

The drug cost of lenalidomide for people who remain on treatment for more than 26 cycles will be met by the company. LENALIDOMIDE MDS NICE TA322 Treatment of patients with transfusion-dependent anaemia (< 8 consecutive weeks without RBC transfusions within 16 weeks prior to commencing treatment) due to low- or intermediate-1-risk

More information

NCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)

NCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel

More information

Fludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia

Fludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Dose Route Diluent Rate 1 Paracetamol 1gram Oral 1 Hydrocortisone 100mg IV bolus 1 Chlorphenamine 10mg IV bolus 1 Rituximab 375mg/m 2 IV infusion

More information

Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer

Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:

More information

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician

ULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group

More information

EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen

EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen y Systemic Anti Cancer Treatment Protocol EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen PROTOCOL REF: MPHAECANBR (Version No: 1.0) Approved for use in: ER positive, HER2 negative ( Luminal

More information

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour Indication: Second line therapy in Relapsed Germ Cell Tumours Regimen details: Paclitaxel 175mg/m 2 IV Cisplatin 20mg/m 2 IV - D5 Ifosfamide

More information

Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen

Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen Systemic Anti Cancer Treatment Protocol Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen PROTOCOL REF: MPHAPCECBR (Version No: 1.0) Approved for use in: Neoadjuvant treatment of operable,

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

Cisplatin and Pemetrexed (NSCLC, mesothelioma)

Cisplatin and Pemetrexed (NSCLC, mesothelioma) Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as

More information

Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma

Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy 1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer

More information

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Oxaliplatin and Gemcitabine

Oxaliplatin and Gemcitabine Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen

More information